FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W8552575> ?p ?o ?g. }

• W8552575 abstract "Abstract Inhibitors of class I/II histone deacetylases (HDACi) possess anti-leukemic activity and have been reported to modulate the function of immune effector cells. Thus, they could provide specific clinical benefit in the allogeneic hematopoietic stem cell transplantation (HSCT) setting. Panobinostat (PAN) is a potent, orally available pan-HDACi reported to either suppress or stimulate regulatory T cells (T reg), depending on the administered dose (Shen L & Pili R, OncoImmunology 1;7:948, 2012). The feasibility and efficacy of PAN treatment following HSCT for patients (pts) with high risk acute myeloid leukemia (AML) has not been established. We report clinical and translational results of the dose-escalation phase of the PANOBEST study with PAN as post-HSCT maintenance. Primary objectives were, based on dose-limiting toxicity (DLT), determining the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) of PAN in patients with high risk AML or myelodysplastic syndromes (MDS) in complete remission (CR) after reduced-intensity conditioning HSCT. Secondary objectives were the evaluation of safety, tolerability and immunoregulatory properties of PAN, and overall (OS) and disease-free survival (DFS) of treated patients. PAN was started at 10 mg p.o. three times a week (TIW) and escalated to 20 and 30 mg TIW using a 3+3 design. Treatment was initiated 60-150 days after HSCT and continued for up to one year. Eligibility criteria included: recovery of peripheral blood counts, adequate organ function and no severe graft versus host disease (GvHD). All pts gave written informed consent. DLT was defined as prolonged grade 4 hematologic or grade 3/4 non-hematologic toxicity within 28 days of the first PAN dose. Immunophenoytyping of lymphocyte subsets was performed pre-treatment and on days 3, 8, 30, 90, 180 and 360. 12 pts (11 AML, 1 MDS), median age of 52 years (21-62) were enrolled. PAN was started within a median of 73 days (60-126) after HSCT, which was performed with active disease (n=11) or in CR2 (n=1). The RP2D was determined to be 20 mg TIW based on one DLT (fatigue grade 3) at 20 mg and two DLTs (nausea/emesis and colitis grade 3 each) at 30 mg. Grade 2-4 adverse events (AEs) were reported in 10 out of the 12 pts (83%). Grade 3/4 AEs included hematologic toxicity (50% of pts), laboratory alterations (33%), gastrointestinal symptoms (25%), fatigue, pulmonary infection (17% each), sepsis, herpes stomatitis, diabetes, syncope, deep vein thrombosis and pulmonary embolism (8% each). Toxicity was reversible and required at least one PAN dose reduction in 3 pts. Acute GvHD grade 2 (1 pt) and 3 (2 pts) was responsive to steroids in 2 pts or salvage therapy in 1 pt. Four pts developed mild (n=3) or moderate (n=1) chronic GvHD. To date, 5 pts have completed one year of PAN and 2 pts remain on treatment (days 238, 290). Five pts discontinued treatment prematurely after 10-217 days due to grade 3 toxicities (n=4) or AML relapse (n=1). With a median follow up of 579 days (129-911), 11/12 pts are alive and 10/12 in continuous CR after HSCT. Seven pts received prophylactic donor lymphocyte infusions (DLIs, 1-5 doses of 0.1-20x106 CD3+ cells/kg). Immunophenotyping revealed no impact of PAN on absolute T reg numbers (9 pts), but a significantly reduced proportion of CD4+CD25++CD127dim/- T reg to CD3+CD4+ T helper (Th) cells by day 8 after 3 doses of PAN (mean±SEM: 14.6±2.6 vs. 9.6±1.2%, p value of t test =0.03). While Treg/Th proportion continuously decreased in pts with ongoing CR, it again increased after PAN discontinuation or remained stable under PAN treatment in both relapsing patients. Outcome of the study population was compared with a historical cohort of 29 consecutive pts with active AML transplanted in Frankfurt in 2000-2009. Both cohorts were similar in age, gender, disease stage or BM blasts at time of HSCT, donor type and use of DLIs. In a landmark analysis including all pts who were in CR and without severe GvHD on day 73 after HSCT, probabilities for DFS and OS at 18 months after HSCT were 83±11% vs. 55±9% (p=0.145, log-rank test) and 92±8% vs.66±9% (p=0.085) in the PANOBEST vs. historical cohort (Fig 1). PAN is well tolerated after HSCT at a RP2D of 20 mg TIW. Comparison with a historical control cohort of pts transplanted with active AML shows a low relapse rate, which appears to be associated with a PAN-induced modulation of the T reg/Th proportion. Disclosures: Bug: Novartis: Honoraria, Travel grants, support for the clinical study Other. Ottmann:Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau." @default.
• W8552575 created "2016-06-24" @default.
• W8552575 creator A5001646221 @default.
• W8552575 creator A5022518487 @default.
• W8552575 creator A5056700746 @default.
• W8552575 creator A5064625563 @default.
• W8552575 creator A5073313603 @default.
• W8552575 creator A5086016311 @default.
• W8552575 creator A5086143409 @default.
• W8552575 creator A5090913228 @default.
• W8552575 date "2013-11-15" @default.
• W8552575 modified "2023-10-01" @default.
• W8552575 title "Post-Transplant Maintenance With The Deacetylase Inhibitor Panobinostat In Patients With High-Risk AML Or MDS: Results Of The Phase I Part Of The Panobest Trial" @default.
• W8552575 doi "https://doi.org/10.1182/blood.v122.21.3315.3315" @default.
• W8552575 hasPublicationYear "2013" @default.
• W8552575 type Work @default.
• W8552575 sameAs 8552575 @default.
• W8552575 citedByCount "4" @default.
• W8552575 countsByYear W85525752014 @default.
• W8552575 countsByYear W85525752015 @default.
• W8552575 crossrefType "journal-article" @default.
• W8552575 hasAuthorship W8552575A5001646221 @default.
• W8552575 hasAuthorship W8552575A5022518487 @default.
• W8552575 hasAuthorship W8552575A5056700746 @default.
• W8552575 hasAuthorship W8552575A5064625563 @default.
• W8552575 hasAuthorship W8552575A5073313603 @default.
• W8552575 hasAuthorship W8552575A5086016311 @default.
• W8552575 hasAuthorship W8552575A5086143409 @default.
• W8552575 hasAuthorship W8552575A5090913228 @default.
• W8552575 hasConcept C104317684 @default.
• W8552575 hasConcept C126322002 @default.
• W8552575 hasConcept C143998085 @default.
• W8552575 hasConcept C185592680 @default.
• W8552575 hasConcept C197934379 @default.
• W8552575 hasConcept C2777408962 @default.
• W8552575 hasConcept C2778305200 @default.
• W8552575 hasConcept C2778375690 @default.
• W8552575 hasConcept C2780225316 @default.
• W8552575 hasConcept C2911091166 @default.
• W8552575 hasConcept C535046627 @default.
• W8552575 hasConcept C55493867 @default.
• W8552575 hasConcept C64927066 @default.
• W8552575 hasConcept C71924100 @default.
• W8552575 hasConceptScore W8552575C104317684 @default.
• W8552575 hasConceptScore W8552575C126322002 @default.
• W8552575 hasConceptScore W8552575C143998085 @default.
• W8552575 hasConceptScore W8552575C185592680 @default.
• W8552575 hasConceptScore W8552575C197934379 @default.
• W8552575 hasConceptScore W8552575C2777408962 @default.
• W8552575 hasConceptScore W8552575C2778305200 @default.
• W8552575 hasConceptScore W8552575C2778375690 @default.
• W8552575 hasConceptScore W8552575C2780225316 @default.
• W8552575 hasConceptScore W8552575C2911091166 @default.
• W8552575 hasConceptScore W8552575C535046627 @default.
• W8552575 hasConceptScore W8552575C55493867 @default.
• W8552575 hasConceptScore W8552575C64927066 @default.
• W8552575 hasConceptScore W8552575C71924100 @default.
• W8552575 hasLocation W85525751 @default.
• W8552575 hasOpenAccess W8552575 @default.
• W8552575 hasPrimaryLocation W85525751 @default.
• W8552575 hasRelatedWork W1574871821 @default.
• W8552575 hasRelatedWork W2524916302 @default.
• W8552575 hasRelatedWork W2531135360 @default.
• W8552575 hasRelatedWork W2535732439 @default.
• W8552575 hasRelatedWork W2535838980 @default.
• W8552575 hasRelatedWork W2547496328 @default.
• W8552575 hasRelatedWork W2548209122 @default.
• W8552575 hasRelatedWork W2548564534 @default.
• W8552575 hasRelatedWork W2552228689 @default.
• W8552575 hasRelatedWork W2554946963 @default.
• W8552575 hasRelatedWork W2559359494 @default.
• W8552575 hasRelatedWork W2560777339 @default.
• W8552575 hasRelatedWork W2566284583 @default.
• W8552575 hasRelatedWork W2572345794 @default.
• W8552575 hasRelatedWork W2573645739 @default.
• W8552575 hasRelatedWork W2601429049 @default.
• W8552575 hasRelatedWork W2978434317 @default.
• W8552575 hasRelatedWork W2979469167 @default.
• W8552575 hasRelatedWork W2979852794 @default.
• W8552575 hasRelatedWork W2994089091 @default.
• W8552575 isParatext "false" @default.
• W8552575 isRetracted "false" @default.
• W8552575 magId "8552575" @default.
• W8552575 workType "article" @default.